To study the effect of an empirical treatment on idiopathic terminal ileitis

To study impact of an empirical protocolized management in patients with Non-specific terminal ileal abnormalities (namely ulcer and nodularity)-A pilot study

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023459

Enrollment

120

Registered

2020-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K639- Disease of intestine, unspecified

Interventions

Intervention1: Group B: Symptomatic treatment: Group B: Symptomatic treatment Intervention2: Group A: Symptomatic and empirical protocolized treatment: Tab.Rifaximin 550mg orally twice orally for 2 we

Eligibility

Inclusion criteria

Inclusion criteria: Age >18 Informed consent Patients who showed terminal ileal ulcers (single or multiple) or nodularity as sole endoscopic abnormality

Exclusion criteria

Exclusion criteria: History of NSAIDs consumption ( History of colorectal surgery History of tuberculosis Oral or genital ulcerations Recent history of intake of Angiotensin receptor blockers. Coincidental ulceration in ileo-cecal valve or colon Known case of inflammatory bowel disease Recent history of gastroenteritis Lymphoma HIV Previous ileal resection.

Design outcomes

Primary

Measure	Time frame
Mucosal healing on Colonoscopy after 3 months of Empirical Protocolized treatment in experimental arm and controlsTimepoint: 3 MONTHS	—

Secondary

Measure	Time frame
NOT APPLICABLETimepoint: NOT APPLICABLE	—

Countries

India

Contacts

Public ContactDr Preetam Nath

KIMS

preetam.nath@kims.ac.in7326086490

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 10, 2026